Lonza Group AG

LONN.SWHealthcare

Sentinellis Health Score

4.2/10

Moderate concerns

Market Cap

CHF 34.1B

Revenue

CHF 6.5B

P/E Ratio

37.5x

AI Summary

Lonza manufactures medicines and biologics under contract for pharmaceutical companies that need specialized production capabilities. They operate three main business lines: Integrated Biologics (growing living cells to make complex drugs), Advanced Synthesis (manufacturing small molecule drugs and antibody-drug conjugates), and Specialized Modalities (cell and gene therapies, mRNA production). Essentially, they are the factory for companies that develop medicines but lack the specialized manufacturing infrastructure to produce them at scale [Yahoo Finance].

Lonza Group AG is a Swiss contract development and manufacturing organization (CDMO) that produces complex medicines for pharmaceutical and biotech companies, operating across biologics, small molecules, and specialized therapies like cell and gene treatments [Yahoo Finance]. The company generated CHF 6.5B in revenue but faces moderate financial concerns with negative free cash flow of CHF -204M and a debt load of 2.8x EBITDA [Yahoo Finance]. With 20,000 employees globally, Lonza is positioned in the high-growth biologics manufacturing sector but trades at a premium 37.5x price-to-earnings ratio [Yahoo Finance].

Lonza shows mixed financial health with solid profitability margins but concerning cash flow and elevated debt levels.

Confidence6/10